PARP inhibitors

Cancer-fighting PARP drugs from AstraZeneca, Clovis and Tesaro largely overpriced, watchdog says
Cancer-fighting PARP drugs from AstraZeneca, Clovis and Tesaro largely overpriced, watchdog says
Fierce Pharma
PARP inhibitors
AstraZeneca
Clovis Oncology
Tesaro
drug pricing
Flag link:
Upstart women’s oncology company in-licenses PhII PARP; Beijing biotech grabs $29M startup round
Upstart women’s oncology company in-licenses PhII PARP; Beijing biotech grabs $29M startup round
Endpoints
oncology
PARP inhibitors
2X Oncology
Eisai
2X-121
Jazz Pharmaceuticals
Flag link:
Is Clovis Oncology A Takeover Candidate?
Is Clovis Oncology A Takeover Candidate?
Seeking Alpha
Clovis Oncology
M&A
rucaparib
PARP inhibitors
Flag link:
Can AstraZeneca Keep Up As Clovis, Tesaro Unveil Blockbuster Drugs?
Can AstraZeneca Keep Up As Clovis, Tesaro Unveil Blockbuster Drugs?
Investors Business Daily
AstraZeneca
Clovis
Tesaro
PARP inhibitors
Flag link:
Tesaro's PARP inhibitor approved in ovarian cancer
Tesaro's PARP inhibitor approved in ovarian cancer
BioPharma Dive
Tesaro
ovarian cancer
PARP inhibitors
niraparib
Flag link:
AZ gears up for FDA filing as PARP inhibitor Lynparza wins big in ovarian cancer trial
AZ gears up for FDA filing as PARP inhibitor Lynparza wins big in ovarian cancer trial
Fierce Pharma
AstraZeneca
PARP inhibitors
Lynparza
FDA
ovarian cancer
clinical trials
Flag link:
Clovis Oncology Secures FDA Approval for New Ovarian Cancer Drug
Clovis Oncology Secures FDA Approval for New Ovarian Cancer Drug
TheStreet.com
Clovis Oncology
FDA
PARP inhibitors
rucaparib
ovarian cancer
Rubraca
Flag link:
AbbVie breast cancer drug falls short in Phase 2
AbbVie breast cancer drug falls short in Phase 2
BioPharma Dive
AbbVie
breast cancer
veliparib
PARP inhibitors
BRCA-mutant breast cancer
Flag link:
Gilead Sciences, Inc. Can Fancy TESARO Inc for Acquisition
Gilead Sciences, Inc. Can Fancy TESARO Inc for Acquisition
Bidness, ETC
Gilead Sciences
PARP inhibitors
Tesaro
M&A
niraparib
Flag link:
Buyout target Medivation says cancer drug could be "best in class"
Buyout target Medivation says cancer drug could be "best in class"
Yahoo/Reuters
Medivation
talazoparib
PARP inhibitors
Sanofi
M&A
Flag link:
An Overnight Double! Could These Drugmakers Be Next?
An Overnight Double! Could These Drugmakers Be Next?
Motley Fool
Tesaro
ovarian cancer
PARP inhibitors
niraparib
AstraZeneca
Lynparza
Medivation
AbbVie
Clovis Oncology
Flag link:
Medivation: It’s Not Just M&A
Medivation: It’s Not Just M&A
Barron's
Medivation
M&A
AstraZenca
Sanofi
Gilead Sciences
talazoparib
PARP inhibitors
Flag link:
Carping Over PARPs: Buyout Equals 'Negative' for BioMarin?
Carping Over PARPs: Buyout Equals 'Negative' for BioMarin?
Bioworld
Biomarin
PARP inhibitors
Flag link:
Sanofi-Aventis to Buy Cancer Drug Firm BiPar
Sanofi-Aventis to Buy Cancer Drug Firm BiPar
TheStreet.com
Sanofi
cancer
Bi-Par
buyouts
PARP inhibitors
Flag link: